Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FARMINGTON HILLS, Mich., Jan. 24, 2024 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that the independent members of its Board of Directors approved equity awards under Ocuphire’s 2021 Inducement Plan, as a material inducement to two new employees in connection with their employment with the Company effective on January 18, 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.
Related news for (OCUP)
- ocuphire pharma announces acquisition of opus genetics
- ocuphire pharma announces publication of full phase 3 results of phentolamine ophthalmic solution 0.75% for pharmacologically-induced mydriasis in ophthalmology
- update – ocuphire pharma initiates vega-3 phase 3 trial evaluating phentolamine ophthalmic solution 0.75% for presbyopia
- ocuphire pharma initiates vega-3 phase 3 trial evaluating phentolamine ophthalmic solution 0.75% for presbyopia
- Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference